Authors
Latest:
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Lymph nodes in bladder cancer: Past, present, and future"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Latest:
UT Money Matters: Are REITs right for your portfolio?Real estate investment trusts (REITs) offer an alternative asset to stocks or bonds that provide a convenient way to get income from rental properties without the risks and commitment of owning directly.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Emulating target trials using observational evidence to inform clinical decision-making"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Latest:
Forward Looking NMIBC Treatment Advancements and Needs in 2024In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
Latest:
Prostate cancer survivor treated at MUSC shares his storyProstate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.
Latest:
Advice for limiting malpractice insurance costsExpert advice for physicians seeking new coverage.
Latest:
Kidney stone treatment inches toward precision medicine"As more genes are classified and catalogued, diagnosis and treatment of kidney stones inches further and further toward 'precision medicine,' " write Rutul Patel, DO, MS, and Alexander Small, MD.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Unsolved Mystery: Where did COVID-19 come from?Questions remain surrounding the origin of the global pandemic.
Latest:
Study shows gender disparities in CKD detection and treatment“We observed profound differences in the detection work up and management of chronic kidney disease suggesting suboptimal care among women,” said Juan Jesus Carrero, PharmD, PhD.
Latest:
Bladder Cancer Advocacy Network (BCAN) announces $600,000 in funding to accelerate breakthroughs in bladder cancer researchAwardees are being recognized for creative approaches to accelerating progress in bladder cancer research.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
GNRH agonists vs antagonists in prostate cancer: How to chooseMany factors play into decision-making process when weighing agents.
Latest:
Malpractice Consult: How attorneys successfully cross-examine expert witnesses"Effective cross-examination can create an implication that an expert’s opinions are motivated by bias or self-interest, rather than a neutral evaluation of the facts. This is frequently accomplished by highlighting the fact that experts are paid for time spent reviewing a case and testifying," writes Kenton H. Steele, Esq.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Unmet Needs, Future Directions, and Clinical Pearls in mCRPCDr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
Latest:
Insights on Perirectal Spacing in Prostate CancerIn the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
Latest:
The Future of Prostate Cancer ImagingProstate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
Clinical Pearls for Community Urologists Treating Patients with MIBCDr Chamie shares advice for community urologists treating patients with MIBC.
Latest:
PSMA PET-CT Imaging: Impact on Real-World Diagnosis and Management of Prostate CancerIn this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.
Latest:
US Urology Partners Names Healthcare Visionary Raoul S. Concepcion, MD, as Chief Science OfficerConcepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
PINNACLE trial aims to confirm pilot success with BPH drug-coated balloon catheterThe drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
